Wild type p53 accumulates in the cytoplasm in a subset of tumors such as neuroblastomas and breast carcinomas through an unknown mechanism. Exclusion of p53 from the nucleus may lead to inactivation of p53 during tumor development. We present evidence that MDM2 plays a signi®cant role in promoting the degradation of nuclear p53 in tumor cells with a cytoplasmic p53 phenotype. Inhibition of MDM2 expression using antisense oligonucleotide, inhibition of MDM2 function by the tumor suppressor ARF or a MDM2 deletion mutant result in the accumulation of nuclear p53. p53 point mutants de®cient in MDM2 binding have increased nuclear localization. Inhibition of nuclear export by leptomycin B also results in retention of nascent p53 in the nucleus, suggesting that cytoplasmic distribution of p53 results from ecient export of nuclear p53 in combination with MDM2-mediated degradation. These results suggest that MDM2 is an important determinant of p53 subcellular distribution and may contribute to p53 inactivation without overexpression. Oncogene (2000) 19, 232 ± 240.
Introduction
The p53 tumor suppressor plays an important role in preventing the development of malignancies. Mutational inactivation of p53 occurs in over half of all cancers (Hollstein et al., 1994) , indicating that the presence of a functional p53 pathway is incompatible with neoplastic cell growth. Tumor cells with p53 mutations or deletion are highly sensitive to exogenously re-introduced wild type p53, whereas tumor cells with wild type p53 are often partially resistant to wild type p53 in clonogenic assays (Baker et al., 1990; Casey et al., 1991) . Therefore, it is possible that many tumors with wild type p53 have also undergone changes that reduced their sensitivity to p53, either by functionally inactivating p53 or inhibiting other steps in the p53 pathway.
Analyses of tumors and tumor cell lines with wild type p53 also revealed evidence suggestive of abnormal p53 functional status, such as increased p53 protein levels (Cordon Cardo et al., 1994) , cytoplasmic localization of p53 (Moll et al., 1992 (Moll et al., , 1995 , and overexpression of the p53 inhibitor MDM2 (Oliner et al., 1992; Cordon Cardo et al., 1994) . Cytoplasmic sequestration of p53 has been detected in 37% of in¯ammatory breast carcinomas and over 95% of undierentiated neuroblastomas (Moll et al., 1992 (Moll et al., , 1995 . Neuroblastoma cell lines with cytoplasmic p53 showed decreased cell cycle arrest response after DNA damaging treatments Isaacs et al., 1998) . This may result from p53 being excluded from the nuclear compartment, where it normally functions as a transcription factor. Therefore, exclusion of p53 from the nucleus may compromise the ability of p53 to exert its tumor suppressor function and may be an important alternative mechanism of p53 inactivation during tumor development.
The cytoplasmic p53 in neuroblastoma cell lines is present in high molecular weight complexes with halflives of about 6 h (Davido et al., 1992; Moll et al., 1996) . Overexpression of a p53 C-terminal fragment can result in the nuclear accumulation of p53 in neuroblastoma cells . Furthermore, residue 305 of p53 has been shown to be important for nuclear import of p53, whereas residues 326 ± 355 is important for cytoplasmic sequestration (Liang et al., 1998) . These observations suggest that formation of cytoplasmic aggregates mediated by the C-terminal domain of p53 is important for the accumulation of p53 in the cytoplasm. However, it is not clear whether this mechanism alone can account for the absence of nuclear p53.
The level and activity of p53 is regulated in part by the MDM2 oncoprotein, which binds to p53 and inhibits its transcription activation function (Momand et al., 1992) . MDM2 binding also promotes p53 degradation through the ubiquitin-dependent proteasome pathway (Haupt et al., 1997; Kubbutat et al., 1997) . MDM2 expression is induced by p53 (Wu et al., 1993; Barak et al., 1993) , thus forming a negative feedback loop that maintains p53 at low levels in the absence of stress. Loss of MDM2 results in embryonic lethality due to activated p53 (Oca Luna et al., 1995; Jones et al., 1995) . Increasing evidence suggests that regulation of the interaction between p53 and MDM2 by phosphorylation (Shieh et al., 1997; Canman et al., 1998; Banin et al., 1998) , and inhibition of MDM2 by the tumor suppressor ARF encoded by the p16/INK4 locus are important mechanisms of p53 activation Pomerantz et al., 1998) . MDM2 can shuttle between the cytoplasm and nucleus. Mutations of the nuclear import or export signals of MDM2 inhibit its ability to promote p53 degradation (Roth et al., 1998; Tao and Levine, 1999b) . ARF induces p53 stabilization by blocking nuclear export of MDM2 (Weber et al., 1999; Zhang and Xiong, 1999; Tao and Levine, 1999a) . Therefore, degradation of p53 requires nuclear shuttling of MDM2.
Recently, p53 has also been shown to contain a NES signal sequence in the tetramerization domain (Stommel et al., 1999) , which is sucient to mediate nuclear-cytoplasmic shuttling of p53 in the absence of MDM2. Overexpression of a minimal p53 tetramerization domain or inhibition of nuclear export by leptomycin B can lead to nuclear p53 accumulation in neuroblastoma cells (Stommel et al., 1999) . These observations are consistent with active nuclear-cytoplasmic shuttling of p53 occurring in tumors with a cytoplasmic p53 distribution.
In this report, we show that interference of MDM2 expression or function by MDM2 antisense oligonucleotide treatment, expression of the ARF tumor suppressor, or a dominant-negative fragment of MDM2 overcome the cytoplasmic p53 phenotype. p53 point mutants de®cient in MDM2 binding are resistant to nuclear exclusion. The results con®rm the involvement of MDM2 in targeting the degradation of a short-lived, actively tracking subpopulation of p53.
Results

Inhibition of MDM2 expression overcomes nuclear p53 exclusion
We previously identi®ed MDM2 antisense oligonucleotides (AS2) that can eciently inhibit MDM2 gene expression in tumor cell lines overexpressing MDM2 . Inhibition of MDM2 expression results in increase of p53 activity . When cell lines with characteristic cytoplasmic wild type p53, such as MCF-7 (breast carcinoma) (Takahashi et al., 1993) , SK-N-SH (neuroblastoma) , and HepG2 (liver carcinoma) were treated with the MDM2 antisense oligonucleotide, strong accumulation of nuclear p53 was observed (Figure 1 ). Accumulation of nuclear p53 is associated with signi®cant induction of the p53 responsive gene p21/ WAF1 expression (not shown), and activation of an integrated p53-inducible luciferase reporter (Figure 2a ), indicating that the nuclear p53 is functionally active.
The eect of the oligonucleotide is speci®cally through the inhibition of MDM2 expression. The low levels of MDM2 expression were inhibited over fourfold after treatment with AS2, and a control oligonucleotide with four mismatches had signi®cantly weaker ability to activate p53 and induce p53 accumulation (Figure 2b ), which correlates with its reduced ability to inhibit MDM2 expression. These results reveal that MDM2 in these cells may play a signi®cant role in inhibiting the accumulation of active p53 in the nucleus.
Inhibition of nuclear export causes nuclear p53 accumulation MDM2 and p53 have been found to have nuclear/ cytoplasmic shuttling properties mediated by characteristic NES signals (Roth et al., 1998; Stommel et al., 1999) . Mutations in the NES or NLS signals of MDM2 inactivate its ability to promote p53 degradation (Roth et al., 1998; Tao and Levine, 1999b) . Thus MDM2 may facilitate nuclear export of p53 and its subsequent ubiquitin-dependent degradation in the cytoplasm. The induction of nuclear p53 by MDM2 antisense oligonucleotide suggests that in cells with cytoplasmic distribution of p53, there may be constant import of a subpopulation of nascent p53 into the nucleus, which is then exported and degraded by MDM2 to maintain cytoplasmic p53 at a steady state level.
To test this possibility, we examined the eect of leptomycin B on nuclear p53 level. Leptomycin B binds to the nuclear export factor Crm1 and prevents Crm1 interaction with NES signals (Fornerod et al., 1997; Fukuda et al., 1997) . If p53 is imported into the nucleus and then rapidly exported, either dependent or independent of MDM2, inhibition of nuclear export function should result in accumulation of p53 in the nucleus. When MCF-7 cells were treated with leptomycin B for 4 h, strong nuclear p53 accumulation was detected by IF staining (Figure 3a ). Nuclear accumulation of p53 was also observed in SK-N-SH cells treated for 8 h with leptomycin B (Figure 3a) (moderately induced at 4 h, not shown), as reported recently (Stommel et al., 1999) . HepG2 cells also showed a rapid accumulation of nuclear p53 similar to MCF-7 (not shown). Leptomycin B treatment also led to strong increases in total p53 and MDM2 levels ( Figure 3b ), but no increase in the control protein poly (ADP-ribose) polymerase (PARP, not shown), suggesting that constant nuclear export function is required to prevent nuclear accumulation of p53. The increase of MDM2 level after laptomycin B treatment may be due to activation of p53. This result indicates that cells accumulating cytoplasmic p53 may in general have a dynamic tracking of nascent p53 between the cytoplasm and nucleus.
To further test whether the signi®cant levels of stable cytoplasmic p53 is also undergoing active nuclear shuttling, MCF-7 and SK-N-SH cells were treated with cycloheximide and leptomycin B for 4 h and stained for p53. If most of the cytoplasmic p53 population is undergoing active nuclear shuttling, leptomycin B should trap the pre-existing p53 in the nucleus. However, this treatment did not lead to redistribution of cytoplasmic p53 into the nucleus (Figure 3a ). This suggests that when protein synthesis is inhibited, most of the pre-existing cytoplasmic p53 is unable to enter the nucleus, probably due to sequestration in the cytoplasm . Therefore, only nascent p53 is active in nuclear import. It is unlikely that cycloheximide blocks nuclear import of cytoplasmic p53, since p53 can shuttle in the presence of cycloheximide (Stommel et al., 1999) .
Active p53 turnover in cells with stable cytoplasmic p53
The above results suggest that active elimination of nuclear p53 is important for maintaining the cytoplasmic p53 phenotype. Since MDM2 promotes degradation of p53 through the ubiquitin dependent pathway, there may be a subpopulation of p53 in these cells that are being rapidly degraded by MDM2, despite a separate stable store of p53 in the cytoplasm.
To test this possibility, the cells were treated with the proteasome inhibitor MG132. Treatment of SK-N-SH and MCF-7 cells with MG132 resulted in signi®cant increase of nuclear p53 (Figure 4a ), as well as increase of total p53 in the cells (Figure 4b ), indicating that there is a nuclear-targeted p53 population being actively degraded. Similar results were also obtained with HepG2 cells (not shown).
In the second experiment, cells were stably transfected with a dominant-negative MDM2 deletion mutant. The MDM2 fragment 1 ± 361 generated by caspase cleavage after residue 361 has lost the ability to promote p53 degradation, but still retains the ability to bind to p53 (Chen et al., 1997; Pochampally et al., 1999) . Overexpression of this MDM2 mutant should block full length MDM2 binding to p53, thus leading to stabilization of p53. Stable transfection of SK-N-SH cells with MDM2 1 ± 361 fragment resulted in strong accumulation of total p53 (Figure 5a ), which is largely localized in the nucleus by Pab1801 staining ( Figure  5b ). MDM2 1 ± 361 stable overexpression cell lines could not be obtained from the transfection of MCF-7 and HepG2 cells, probably due to the toxicity of MDM2 overexpression observed in certain cell lines (Brown et al., 1998) . These experiments further con®rm the role of MDM2 in promoting rapid turnover of nuclear p53. The results are also consistent with a previous ®nding that MCF-7 cells contain unstable p53 
Overexpression of ARF overcomes p53 nuclear exclusion
The rapid turnover of nuclear p53 in MCF-7, SK-N-SH, and HepG2 suggests that the ability of MDM2 to promote nascent p53 degradation may be highly ecient in these cells compared to cells that have nuclear p53. Since MDM2 may function as a ubiquitin ligase, it is possible that it can act catalytically to promote ecient p53 degradation without overexpression. In order to further test whether MDM2 is responsible for elimination of nuclear p53, we examined the eect of ARF expression. ARF has been found to regulate the activity of p53 through interaction with MDM2. Overexpression of ARF can stabilize p53, reduce the level of p53 ubiquitination, and inhibit the ubiquitin ligase activity of MDM2 Pomerantz et al., 1998; Stott et al., 1998; Honda and Yasuda, 1999) . When MCF-7 and SK-N-SH cells were transiently transfected with a cDNA plasmid encoding human ARF, strong nuclear p53 accumulation was detected (Figure 6a ). Nuclear accumulation of p53 was also induced by transfecting an N-terminal fragment (1 ± 64), but not the C-terminal fragment (65 ± 133) of ARF (not shown), consistent with the ability of the N-terminal fragment to induce growth arrest (Quelle et al., 1997) . Furthermore, expression of ARF led to increased total p53 and MDM2 levels (Figure 6b ). These results suggest that ARF-regulated Figure 3 Inhibition of nuclear export by leptomycin B induces nuclear accumulation of nascent p53. (a) Cells were treated with 10 ng/ml of leptomycin B (LMB) for 4 h (MCF-7) or 8 h (SK-N-SH). Leptomycin B (10 ng/ml) and cycloheximide (CHX, 25 mg/ ml) coincubations were carried out for 4 h. p53 was detected by staining with Pab1801. Pre-existing cytoplasmic p53 did not enter the nucleus when nascent p53 synthesis was inhibited by cycloheximide. (b) Cells were treated with indicated concentrations of leptomycin B for 4 h (MCF-7 and HepG2) or 8 h (SK-N-SH). MDM2 and p53 levels were determined by direct Western blot using 3G9 or DO-1 antibodies MDM2 activities are necessary for eliminating nuclear p53.
It is unclear whether nuclear exclusion of p53 in these cell lines is directly caused by de®ciencies in ARF function. Endogenous ARF was not detectable in MCF-7 and SK-N-SH cells by Western blot using an antiserum against human ARF (not shown). MCF-7 has a deletion of the p16INK4 locus and has no detectable ARF mRNA (Zariwala and Xiong, 1996; Stott et al., 1998) . Further investigation will be needed to establish a correlation between ARF expression level and p53 localization.
Interaction with MDM2 is important for cytoplasmic localization of p53
If MDM2 plays a role in promoting nuclear export and degradation of p53, loss of MDM2 binding may alter the localization of p53. To test this possibility, MCF-7 cells were transiently transfected with expression plasmids encoding CMV promoter-driven wild type p53, H175, 14/19 and 22/23 point mutants. The tumor-derived H175 mutant is de®cient in transcriptional activation, but competent in binding to MDM2 (Chen et al., 1993) . Both 14/19 and 22/23 double-point mutants are de®cient in binding to MDM2 (Lin et al., 1994) . The 14/19 mutant is active in transcriptional activation and cell cycle arrest, the 22/23 mutant is inactive for both functions (Lin et al., 1994; Chen et al., 1996) . The 14/19 mutant is resistant to inhibition by MDM2 (Chen et al., 1995) .
Transient transfection of MCF-7 resulted in high level p53 expression in a subset of cells after staining with Pab1801, which were readily distinguishable from the untransfected cells (Figure 7 ). The cells were examined for p53 localization with the aid of DAPI nuclear staining. The cells were categorized as having exclusively nuclear p53 or cytoplasmic and diused p53. Within the`cytoplasmic/diused' category, approximately half showed higher cytoplasmic level than nuclear level (see Figure 7 for example) and half showed even cytoplasmic and nuclear distribution, although a clear sub-division of this class was not attempted.
Examination of the transfected cells showed that *50% of wild type p53 transfected cells have nuclear p53, *50% have diused/cytoplasmic p53 ( Figure 7 and Table 1 ). In the H175 mutant transfected cells, *30% showed nuclear p53, *70% showed cytoplasmic/diused p53. In contrast, the 14/19 and 22/23 mutants showed nuclear localization in *90 ± 95% of cells and diused/cytoplasmic localization in *5 ± 10% of cells. Co-expression of MDM2 increased the frequencies of cytoplasmic localization of wild type p53 and the H175 mutant, but had no eect on the (Table 1) . There was also a signi®cant eect of MDM2 co-expression in improving the`quality' of the`cytoplasmic/diused' group, increasing the majority of cells in this group into exclusive cytoplasmic staining (not shown). These results demonstrate that interaction with MDM2 is important for p53 cytoplasmic localization. A similar experiment using SK-N-SH was uninformative due to low p53 expression levels.
Discussion
A signi®cant role of MDM2 in the nuclear exclusion of p53 in neuroblastomas and other cell types was previously considered unlikely because of the absence of MDM2 gene ampli®cation or overexpression in these cells. However, the results presented here demonstrate the perturbation of MDM2 activity by a variety of methods all lead to nuclear accumulation of p53. These observations suggest that despite being present at low levels, MDM2 plays a crucial role in the degradation of nascent p53 and preventing accumulation of p53 in the nucleus. This is consistent with recent ®ndings that MDM2 has ubiquitin ligase E3 activity and nuclear/cytoplasmic shuttling properties (Roth et al., 1998; Honda et al., 1997) , which may enable it to function catalytically at sub-stochiometric levels to regulate p53.
The results are consistent with a model in which nascent p53 undergoes rapid nuclear import and export, which is then degraded in a proteasomedependent manner mediated by MDM2 (Figure 8 ). Three mechanisms may be responsible for causing the absence of nuclear p53. First, p53 nuclear export may be hyper-active due to deregulation of its intrinsic nuclear export function (Stommel et al., 1999) , which is then degraded by MDM2 in the cytoplasm. In such a case, MDM2 function is essential, but it is not a causative factor of p53 nuclear exclusion. Second, p53 may be exported into the cytoplasm at a normal rate, but it is degraded more eciently once entering the cytoplasm due to hyper-active MDM2. Third, nuclear export and degradation of p53 may be a coupled process mediated by MDM2, hyper-active MDM2 may lead to hyper-active p53 nuclear export and subsequent degradation. To date, the nuclear export eciency of p53 in cells with cytoplasmic p53 has not been directly compared to cells with nuclear p53. Our data do not distinguish between these mechanisms.
The results suggest that cytoplasmic accumulation of p53 is due to a combination of dynamic and static processes. p53 accumulates in cytoplasmic complexes, which may represent the stable pool of p53 with a halflife of about 6 h (Davido et al., 1992) . The majority of pre-existing cytoplasmic p53 appears incapable of undergoing rapid nuclear import, which is consistent with its presence in high molecular weight complexes . However, inhibition of proteasomes of nuclear export results in dramatic increase of total p53. This indicates that there is also active synthesis of nascent p53, which undergoes a dynamic process of rapid nuclear import, export, and degradation. MDM2-mediated degradation is important for elimination of most nascent p53, preventing their accumulation in the nucleus. MDM2 may also contribute to the accumulation of stable cytoplasmic p53 by promoting p53 nuclear export, thus increasing the exposure of p53 to cytoplasmic sequestration. Therefore, nascent p53 and the stable cytoplasmic p53 appear to be two distinct populations. Since no signi®cant cytoplasmic MDM2 was detected in the cell lines used in this study, MDM2 is unlikely to be the hypothetical cytoplasmic anchor for p53.
The reason for p53 accumulation in the nucleus after MG132 treatment or p60 MDM2 fragment overexpression is unclear. It is possible that MG132 treatment also blocks nuclear export by stabilizing inhibitors of export. p60 may sequester p53 in the nucleus by blocking its interaction with full length MDM2 or other export factors. Increase of total p53 level may also saturate the cytoplasmic storage capacity or lead to formation of p53 tetramers with concealed nuclear export signals (Stommel et al., 1999) .
The low levels of MDM2 in neuroblastoma cells suggest that MDM2 may be functionally more active in eliminating nuclear p53. It is likely that the ability of MDM2 to promote p53 degradation or export is a regulated process in the absence of DNA damage. The subcellular distribution of p53 changes in dierent stages of the cell cycle (Shaulsky et al., 1990) , suggesting that there are mechanisms that regulate its shuttling and degradation. Choriocarcinoma cell lines often contain high levels of MDM2 and stable nuclear p53 (Landers et al., 1994) , which may be an opposite example to neuroblastoma cells. It is possible that abnormal regulation of p53 nuclear export or degradation occurs in some tumors, leading to inactivation of p53. For example, increased nuclear export of p53 or hyperactive MDM2 may be a characteristic of neuroblasts, which provides an advantage during malignant growth.
The ability of ARF to overcome p53 nuclear exclusion suggests that loss of ARF expression or function may be a potential mechanism for the cytoplasmic p53 phenotype. The eect of ARF in our experiments could be due to inhibition of MDM2-mediated p53 ubiquitination (Honda and Yasuda, 1999) , resulting in saturating amounts of p53 that accumulate in the nucleus. Alternatively, ARF binding to MDM2 may directly inhibit p53 nuclear export. Consistent with this hypothesis, overexpression of ARF has recently been shown to sequester MDM2 into nucleoli and induce nuclear p53 accumulation (Weber et al., 1999) . Inactivation of the MDM2 NLS signal abrogates its ability to promote p53 degradation (Tao and Levine, 1999b) , suggesting that MDM2 must form 
Cells expressing exogenous p53 were counted and divided as containing predominantly nuclear p53 or diused/cytoplasmic p53. Co-transfections with MDM2 were performed using equal amounts of CMV promoter-driven p53 and MDM2 plasmids. The frequencies of each type are also indicated Figure 8 A model for the role of MDM2 in p53 nuclear exclusion. Nascent p53 enters the nucleus guided by its nuclear localization signal. MDM2 expression is induced by nuclear p53, resulting in the formation of p53-MDM2 complex. p53-MDM2 complex formation may enhance p53 nuclear export and is essential for preventing accumulation of nuclear p53. Most of the nascent p53 is degraded by the proteasomes. A small fraction of p53 may also be sequestered in the cytoplasm and become stabilized MDM2 contributes to p53 nuclear exclusion W Lu et al a complex with p53 in the nucleus, and probably exported with p53 as a complex in order to promote p53 degradation. Further analysis of ARF expression will be required to test whether it is involved in nuclear exclusion of p53. Murine ®broblasts derived from ARF-null mouse do not exhibit p53 nuclear exclusion (unpublished result), suggesting that ARF may only be one of the potential regulators. It has been reported that p53 is localized in the cytoplasm of N-type neuroblastoma cells, and in the nucleus of the dierentiated, non-tumorigenic S-type cells (Isaacs et al., 1998) . We also con®rmed this observation in spontaneously dierentiated SK-N-SH cells during this study (unpublished results) . This suggests that the ability of MDM2 to regulate p53 nuclear export and degradation may be modulated by cell dierentiation. The cytoplasmic p53 phenotype in neuroblastomas may be associated with a speci®c dierentiation stage of neural crest cells in which p53 function is tightly controlled by nuclear exclusion. This may contribute to p53 inactivation during tumor development. The results suggest that inhibiting MDM2 expression or function may be an eective approach to reactivate p53 in this class of tumors.
Nuclear exclusion of p53 is frequently observed in experiments using the murine temperature-sensitive valine 135 mutant at the non-permissive temperature (Martinez et al., 1991; Gannon and Lane, 1991) . Whether this phenomenon is related to the nuclear exclusion of wild type p53 in human tumors is unclear. The valine 135 mutant has a signi®cantly altered conformation and is bound to hsp70 protein at 398C (Martinez et al., 1991) , therefore it is likely to be sequestered in the cytoplasm through a dierent mechanism.
In summary, the results presented here reveal an important role of MDM2 in the inactivation of p53 via a nuclear exclusion mechanism. The results suggest that MDM2 may be an important inhibitor of p53 even when expressed at low levels. Therefore, MDM2 may play a broader role in the functional inactivation of p53 during tumor development than has been suggested by the frequency of overexpression. Further investigation into the mechanism of MDM2-mediated p53 nuclear exclusion may provide new information on the regulation of p53 and reveal new targets for therapeutic intervention.
Materials and methods
Cell lines and reagents
SK-N-SH, MCF-7, SH-Sy5Y, and HepG2 cells were obtained from the American Type Cell Collection and maintained in DMEM medium with 10% fetal bovine serum (FBS). Plasmids encoding Myc epitope-tagged human full length ARF, ARF 1 ± 64, and ARF 65 ± 133 in pcDNA3 vector were kindly provided by Dr Yue Xiong . Expression vector encoding MDM2 1 ± 361 mutant was described previously (Chen et al., 1997) . The Gln14/Ser19 double point mutant, and the Leu22/Ser23 double point mutant were also described previously (Lin et al., 1994) . Leptomycin B was kindly provided by Dr Arnold J Levine. The proteasome inhibitor MG132 was purchased from BioMol.
Antisense oligonucleotides
The characterization of MDM2 antisense phosphorothioate oligodeoxynucleotides was described elsewhere . AS2 (5'-TGACACCTGTTCTCACTCAC is an effective MDM2 antisense oligonucleotide. AS2M4 (5'-TGACTCTTGTCCTTACTCAC) is a four base pair mismatch control for AS2. K (5'-CAGAGCCTTCATCTTCC-CAG) is a control oligonucleotide against an unrelated ion channel gene.
Antisense oligonucleotide treatment
Cells were cultured in DMEM medium with 10% FBS. Before addition of oligonucleotides, cells were refed with DMEM containing 1% FBS. Lipofectin (Gibco BRL) was incubated with serum-free DMEM medium for 45 min, then mixed with the oligonucleotides for 10 min and added to the cell culture. The ®nal concentration of Lipofectin was 7 mg/ ml, ®nal concentration of FBS was 0.75%, and oligonucleotide was 200 nM. Cells were incubated with oligonucleotides and Lipofectin for 18 ± 24 h.
Immuno¯uorescence staining of p53
Cells were ®xed with acetone-methanol (1 : 1) for 3 min at room temperature, then blocked with PBS+10% normal goat serum (NGS) for 20 min, and incubated with Pab1801 hybridoma supernatant for 2 h. Slides were washed with PBS+0.1% Triton X-100, incubated with FITC-goat-anti-mouse IgG in PBS+10% NGS for 1 h, washed with PBS+0.1% TritonX-100 and mounted. Photographs were taken using a Zeiss Axioskop I microscope with a digital camera.
Transfection
In a stable transfection, 2610 6 cells were seeded into 10 cm dishes for 24 h and transfected with 15 mg plasmid using the calcium phosphate precipitate protocol. Two days after transfection, cells were cultured in medium containing 750 mg/ml G418 for 2 weeks, G418-resistant colonies were cloned or pooled for analysis. Transient transfection of plasmids were performed using the FuGENE 6 reagent (Boeheringer Mannheim) as recommended by the supplier.
Western blot
Cells were lysed in RIPA buer (1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 50 mM Tris pH 7.4, 150 mM NaCl, 1 mM PMSF), centrifuged for 5 min at 10 000 g and the insoluble debris were discarded. Cell lysate (100 ± 300 mg protein) was fractionated by SDS ± PAGE and transferred to Immobilon P ®lters (Millipore) using a semi-dry electro-blotting apparatus. The ®lter was blocked for 5 min with phosphatebuered saline (PBS) containing 5% non-fat dry milk, 0.1% Tween-20 and then incubated for 1 h with 1/10 dilution of anti-MDM2 monoclonal antibody 3G9 (Chen et al., 1993) in PBS containing 5% non-fat dry milk. For detection of p53, the ®lter was incubated with 1 : 500 dilution of antibody DO-1 (Oncogene Science). The ®lter was then washed four times (5 min each) with PBS containing 0.1% Tween-20. Bound primary antibody was detected by incubating for 1 h with protein A-peroxidase diluted in PBS containing 5% non-fat dry milk. The ®lter was washed with PBS containing 0.1% Tween-20 and developed using the ECL-plus reagent (Amersham). For IP-Western blots, cell lysates containing 100 ± 300 mg protein were incubated with Pab421, Pab1801, or anti-myc antibodies and protein A-Sepharose beads for 4 h at 48C with tumbling. The beads were washed three times with lysis buer (0.5% NP40, 50 mM Tris pH 8.0, 5 mM EDTA, 150 mM NaCl, 1 mM PMSF), boiled in SDS-sample buer and fractionated by SDS ± PAGE.
